30
CARDIOVASCULAR
hamburger

Innovative Stent Design

XIENCE™ Stent is not like other DES—it is the DES proven to provide uncompromising clinical results during and far beyond the intervention, not only helping interventional cardiologists (ICs) achieve enduring and positive patient outcomes, but also enabling patients to experience improved quality of life.¹

XIENCE™ Stent is uniquely designed for exceptional performance1

XIENCE™ Stent is designed to deliver uncompromising clinical success based on a unique combination of stent design, fluoropolymer and drug.

Innovative Stent Design

  • Flexible stent and delivery system offers conformability to vessel anatomy2
  • Low metal-to-artery ratio reduces injury and/or inflammation3
  • Thin, well-apposable struts for rapid re-endothelialization, healing and reduced thrombogenicity4
XIENCE™ Stent design is the reason for its safety and uncompromising clinical results

Anti-Thrombotic Fluoropolymer

The XIENCE™ Stent is significantly more anti-thrombotic than other DES5 due to:

  • Less platelet adhesion
  • Less inflammation
  • Coating that is durable and flexible
The XIENCE™ Stent fluoropolymer is more anti-thrombotic than competitors' stents

Market-Leading Everolimus3

  • 15,000,000 implants worldwide
  • Most studied and used DES
  • Elution rate or everolimus matches restenosis cascade6
  • Low drug dose6,7
  • Broad therapeutic range6
Low doses of Everolimus, the market-leading drug for drug-eluting stents, enhance XIENCE™ Stent safety

Just as the stent design is critical to patient outcomes and quality of life, so are the polymer coatings and the drug elution profile.

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Baron S, et al. J Am Coll Cardiol. 2017;70:3113-3122. Data on file at Abbott.
  2. Colombo A, et al. J Am Coll Cardiol. 2002;40:1021-1033.
  3. Data on file at Abbott.
  4. Kolandaivelu K, et al. Circulation. 2011;123;1400-1409. Kastrati A, et al. Circulation. 2001;103;2816-2821.
  5. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74(Suppl B): TCT-291.
  6. Perkins LEL, et al. J Interven Cardiol. 2009;22:S28-S40.
  7. Ding N, et al. J Interv Cardiol. 2009;22:S18-S27.

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

MAT-2010598 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.